leisure time -WSS

leisure time

author：focus 2025-09-30 00:35:53 - browse：4

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

knowledge

WSS

Tocagen's brain cancer gene therapy trial continues. Investors worry

Affordable Connectivity Program vital to health care, experts say

Ending racial health disparities hinges on penalties, political will

At ASCO, AstraZeneca reports strong data for breast cancer drug

Winning ticket for $1 billion Powerball jackpot sold in California

focus

leisure time

Wikipedia

Supreme Court strikes down use of affirmative action

Shifting the focus from loneliness to social health

New air purifier tech could be key to improving indoor air quality

At ASCO, AstraZeneca reports strong data for breast cancer drug

The high cost of giving birth even with insurance

Hospitals struggle to profit from CAR

Peter Hotez and the public health issue of online harassment

Ultragenyx gene therapy for rare liver ailment succeeds in late

Medical leaders decry Supreme Court decision on affirmative action

Stanford president's case begs question: Who takes blame?

knowledge

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

NIH documents show early flaws of $1.6 billion long Covid program

Driven by the pandemic, applicants flood public health schools

Texas Department of Public Safety speaks out on migrant abuse allegations

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

leisure time

knowledge

knowledge

Wikipedia